

Sheet

1

of

1



0020-5388PUS1

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are n d to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/B/PTO Application Number 10/540.878 INFORMATION DISCLOSURE Filing Date June 27, 2005 STATEMENT BY APPLICANT Takavuki KAWAGUCHI First Named Inventor Art Unit (Use as many sheets as necessary) Examiner Name Not Yet Assigned

Attorney Docket Number

U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				

FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁰				
	BA	WO-99/42439	08-26-1999			1				

"EQUALINE: Intial ir reference considered, whether or not distion is inconformance with MPEP 605. Draw line through classics if not in conformance and not considered, include copy of this form with next communication is applicant. "Applicant is unique classion designation number (optional)." See Monte Codes of USPP 706. In the Codes of USPP 706. The Codes of USPP 7

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	CA	Harwalkar, G.S. et al., "Synthesis and Reactions of 2-Substituted-4H-Benzofuro[3,2-d]-m-Oxazin-4-Ones," Indian Journal of Heterocyclic Chemistry, Vol. 3, April-June 1994, pp. 247-252.			
	СВ	Sogorinsho 41:2913-2918, 1992 and English short summary.			
	СС	Freedman, Michal D., "Oral Anticoagulants: Pharmacodynamics, Clinical Indications and Adverse Effects," J. Clin. Pharmacol. 1992;32:196-209.			
	CD	Hirsh, Jack, "Oral Anticoagulant Drugs," The New England Journal of Medicine, Vol. 324, No. 26, June 1991; pp. 1865-1875.			
	CE	Sixma, Jan J. et al., "The Ideal Anti-Thrombotic Drug," Thrombosis Research, 1992, Vol. 68, pp. 507-512.			
	CF	Matsuo, O. ed., "t-PA and Pro-UK," Gakusaikikaku, 1986, pp. 5-40.			
	CG	Kaiser, Brigitte et al., "Pharmacological Characterization of a New Highly Effective Synthetic Thrombin Inhibitor," Biomed. Biochim. Acta 44 (1985) 7/8, pp. 1201-1210.			
	СН	Tidwell et al., Thrombosis Research, 19, 339-349, 1980.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

/Rebecca Anderson/ 06/02/2008